Delstrigo® Tablets for HIV‑1: Ingredients, Dosage, Safety, and Savings

What Delstrigo® Is and How It Works

Delstrigo® is a complete, once-daily antiretroviral regimen for HIV‑1. Each tablet contains three medicines: doravirine (a non-nucleoside reverse transcriptase inhibitor), lamivudine, and tenofovir disoproxil fumarate. The combination blocks HIV reverse transcriptase at different points, reducing viral replication and helping achieve and maintain viral suppression. This page covers Delstrigo usage, Delstrigo form, Delstrigo dosage, and Delstrigo safety to support informed care. Many patients ask about Delstrigo without insurance, Delstrigo cost, and practical ways to save.

YouDrugstore is a licensed Canadian pharmacy headquartered in Manitoba, and prescriptions are reviewed by licensed pharmacists before dispensing.

Indications include initial therapy in adults and adolescents (≥35 kg) with no known resistance to the components, or to replace a current regimen in virologically suppressed patients without prior failure or resistance to doravirine, lamivudine, or tenofovir disoproxil fumarate. The tablets are taken by mouth, with or without food, once daily.

Delstrigo efficacy has been shown in clinical trials where most participants reached undetectable viral loads over time when adherent. Because the product is a fixed-dose combination, renal function and potential drug interactions must be assessed before therapy is started or switched.

Dosage and Usage

• Standard dose: one tablet once daily by mouth, with or without food.
• Each tablet contains doravirine 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg.
• Use in adults and adolescents (≥35 kg) with no known resistance to any component.
• Do not use with strong CYP3A inducers (for example: rifampin, carbamazepine, phenytoin, St. John’s wort, enzalutamide, mitotane). These can lower doravirine levels and may cause treatment failure.
• Renal impairment: because the combination includes tenofovir disoproxil fumarate, the product is generally not recommended if significant renal dysfunction is present, where component dose adjustments would be required.
• Hepatitis B coinfection: lamivudine and tenofovir have activity against hepatitis B virus. Severe acute exacerbations of hepatitis B can occur after stopping these agents; monitor hepatic function if therapy is discontinued.
• Missed dose: take as soon as remembered unless it is almost time for the next dose. Do not take two doses at once.
• Swallow tablets whole. If a dose is vomited soon after administration, follow the advice from a healthcare professional based on timing.

• Store Delstrigo tablets at 20–25 °C (68–77 °F); excursions 15–30 °C (59–86 °F).
• Keep tablets in the original bottle with the desiccant to protect from moisture.
• Traveling: pack doses in original labeled containers in carry-on luggage. Bring extra tablets in case of delays.
• Avoid excessive heat or freezing during transit. Use an insulated pouch if temperatures are extreme.
• For home storage, keep the bottle tightly closed and away from humidity.

Benefits and Savings

Delstrigo brand is a single-tablet regimen designed for convenience and adherence. Once-daily dosing with or without food helps simplify routines. Trials demonstrated noninferior virologic suppression compared with standard multi-tablet regimens when started in appropriate patients. Many patients value the straightforward Delstrigo usage and the well-characterized Delstrigo side effects profile.

Ordering from YouDrugstore offers access to Canadian pricing. Typical savings range 60–80% versus many US cash markets, which can help when paying without insurance. Multi-month supplies and periodic bulk promotions can lower the per-month Delstrigo price.

For current promotions, see our Delstrigo coupon page.

We also work with licensed, vetted partner pharmacies internationally so we can supply authentic brand medications across a broad range at competitive prices.

Side Effects and Safety

• Common: nausea, diarrhea, headache, dizziness, fatigue, abnormal dreams, trouble sleeping.
• Lab changes: increases in serum creatinine may reflect renal effects; small lipid changes can occur; monitor liver enzymes if indicated.
• Bone and renal risks: tenofovir disoproxil fumarate can reduce bone mineral density and may cause renal tubular dysfunction, including Fanconi syndrome.
• Hepatic: lactic acidosis and severe hepatomegaly with steatosis have been reported with nucleoside analogues; discontinue if suspected.
• Immune reconstitution syndrome can occur after initiating antiretroviral therapy.
• Drug interactions: avoid strong CYP3A inducers; review all prescription, OTC, and herbal products.

Seek urgent care for symptoms of lactic acidosis (for example, deep rapid breathing, persistent nausea, unusual weakness) or severe liver problems (for example, jaundice, dark urine, abdominal pain). In those with hepatitis B coinfection, hepatic flares may occur after stopping therapy; monitor closely under medical supervision.

Onset Time

Viral load typically declines within the first 2–4 weeks of consistent daily dosing. Many adherent patients reach undetectable viral levels by 8–24 weeks, depending on baseline viral load and resistance profile. CD4 counts generally improve over months with ongoing suppression. Symptom changes may be gradual and can vary with individual health status.

Compare With Alternatives

Single-tablet alternatives include bictegravir/emtricitabine/tenofovir alafenamide (often chosen for patients who benefit from the tenofovir alafenamide formulation), and dolutegravir/lamivudine, a two-drug regimen suitable for select patients without hepatitis B coinfection or relevant resistance. These options differ in drug–drug interaction profiles and renal and bone considerations.

Other once-daily combinations, such as dolutegravir/abacavir/lamivudine, may be appropriate for patients who are HLA‑B*5701 negative and without cardiovascular risk concerns related to abacavir. Protease inhibitor–based single-tablet regimens (for example, darunavir/cobicistat/emtricitabine/tenofovir alafenamide) offer high barriers to resistance but have distinct interaction profiles and tolerability considerations.

Combination Therapy

• Delstrigo is a complete regimen and is generally not combined with additional antiretrovirals.
• Avoid coadministration with other lamivudine- or tenofovir-containing products.
• Opportunistic infection prophylaxis (for example, trimethoprim/sulfamethoxazole) may be used concurrently when clinically indicated; review interactions.
• Acid-reducing agents and polyvalent cations do not significantly affect doravirine; still assess all concomitant medications for interaction risks.
• If a change in therapy is required, transition under medical supervision to avoid resistance or hepatitis B flares.

Patient Suitability and Cost-Saving Tips

Candidates include adults and adolescents (≥35 kg) initiating therapy without known resistance, or those switching from a stable, suppressed regimen without previous failure. Not suitable where component resistance is present, with significant renal impairment needing dose adjustments, or with strong CYP3A inducers that decrease doravirine exposure.

Use caution in patients with osteoporosis risk, prior renal disease, or hepatitis B coinfection. Pregnancy and breastfeeding require individualized risk–benefit discussions. Regular monitoring of viral load, CD4 count, renal function, and bone health supports ongoing safety.

To manage Delstrigo cost, consider larger fills when appropriate. Multi-month orders can decrease the average monthly Delstrigo cash price. You can set gentle reorder reminders in your account to avoid gaps in therapy and reduce out-of-pocket disruptions. Customer-service chat is available during posted hours to help with ordering steps.

Authoritative Sources

Delstrigo Prescribing Information (Merck)

Health Canada Drug Product Database: Delstrigo

FDA Label: Delstrigo

Order Delstrigo® from YouDrugstore: add to cart, upload your prescription, and we ship with prompt, express shipping.

This material is educational and does not replace advice from your healthcare professional. Always consult your prescriber and pharmacist for guidance specific to your care.